Bothnia retinal dystrophy
diseaseOn this page
Also known as Vasterbotten dystrophyVC$sterbotten dystrophyVästerbotten dystrophy
Summary
Bothnia retinal dystrophy (MONDO:0011838) is a disease caused by RLBP1 (GenCC Definitive), with 1 cohort gene.
At a glance
- Prevalence: Unknown (Worldwide) [Orphanet-validated]
- Causal gene: RLBP1 (GenCC Definitive)
- Cohort genes: 1
- ClinVar variants: 21
- Phenotypes (HPO): 23
Clinical features
Signs & symptoms
Clinical features (HPO)
23 HPO clinical features (Orphanet curated; top 23 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0000529 | Progressive visual loss | Very frequent (80-99%) |
| HP:0000551 | Color vision defect | Very frequent (80-99%) |
| HP:0001123 | Visual field defect | Very frequent (80-99%) |
| HP:0030469 | Abnormal dark-adapted electroretinogram | Very frequent (80-99%) |
| HP:0030474 | Undetectable dark-adapted electroretinogram | Very frequent (80-99%) |
| HP:0030618 | Increased OCT-measured foveal thickness | Very frequent (80-99%) |
| HP:0000493 | Abnormal foveal morphology | Frequent (30-79%) |
| HP:0000539 | Abnormality of refraction | Frequent (30-79%) |
| HP:0000546 | Retinal degeneration | Frequent (30-79%) |
| HP:0000580 | Pigmentary retinopathy | Frequent (30-79%) |
| HP:0000608 | Macular degeneration | Frequent (30-79%) |
| HP:0007814 | Retinal pigment epithelial mottling | Frequent (30-79%) |
| HP:0032118 | Retinitis | Frequent (30-79%) |
| HP:0000510 | Rod-cone dystrophy | Occasional (5-29%) |
| HP:0000603 | Central scotoma | Occasional (5-29%) |
| HP:0000610 | Abnormal choroid morphology | Occasional (5-29%) |
| HP:0000662 | Nyctalopia | Occasional (5-29%) |
| HP:0001129 | Large central visual field defect | Occasional (5-29%) |
| HP:0007722 | Retinal pigment epithelial atrophy | Occasional (5-29%) |
| HP:0007984 | Electronegative electroretinogram | Occasional (5-29%) |
| HP:0030528 | Paracentral scotoma | Occasional (5-29%) |
| HP:0030529 | Ring scotoma | Occasional (5-29%) |
| HP:0007737 | Bone spicule pigmentation of the retina | Excluded (0%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Bothnia retinal dystrophy |
| Mondo ID | MONDO:0011838 |
| MeSH | C564392 |
| OMIM | 607475 |
| Orphanet | 85128 |
| DOID | DOID:0050683 |
| ICD-11 | 2110390212 |
| SNOMED CT | 715647007 |
| UMLS | C1843816 |
| MedGen | 334499 |
| GARD | 0016734 |
| Is cancer (heuristic) | no |
Also known as: Bothnia retinal dystrophy · Vasterbotten dystrophy · VC$sterbotten dystrophy · Västerbotten dystrophy
Data availability: 21 ClinVar variants · 3 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by body system or component › nervous system disorder › retinal disorder › retinal degeneration › inherited retinal dystrophy › RLBP1-related retinopathy › Bothnia retinal dystrophy
Related subtypes (2): fundus albipunctatus, Newfoundland cone-rod dystrophy
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
21 retrieved; paginated sample, class counts are floors:
6 pathogenic/likely pathogenic, 5 likely pathogenic, 4 pathogenic, 3 uncertain significance, 2 conflicting classifications of pathogenicity, 1 benign
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 1074473 | NM_000326.5(RLBP1):c.466C>T (p.Arg156Ter) | RLBP1 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 13097 | NM_000326.5(RLBP1):c.452G>A (p.Arg151Gln) | RLBP1 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 13100 | NM_000326.5(RLBP1):c.700C>T (p.Arg234Trp) | RLBP1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 13101 | NM_000326.5(RLBP1):c.677T>A (p.Met226Lys) | RLBP1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1400422 | NM_000326.5(RLBP1):c.250del (p.Val84fs) | RLBP1 | Pathogenic | criteria provided, single submitter |
| 1482179 | NM_000326.5(RLBP1):c.832del (p.Gln278fs) | RLBP1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 191289 | NM_000326.5(RLBP1):c.286_297del (p.Phe96_Phe99del) | RLBP1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4277810 | NM_000326.5(RLBP1):c.12+1G>A | RLBP1 | Pathogenic | criteria provided, single submitter |
| 503712 | NM_000326.5(RLBP1):c.141+2T>C | RLBP1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 844049 | NM_000326.5(RLBP1):c.282del (p.Phe95fs) | RLBP1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1066003 | NM_000326.5(RLBP1):c.12+2del | RLBP1 | Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 3064481 | NM_000326.5(RLBP1):c.341T>C (p.Leu114Pro) | RLBP1 | Likely pathogenic | criteria provided, single submitter |
| 3065593 | NM_000326.5(RLBP1):c.203del (p.Glu68fs) | RLBP1 | Likely pathogenic | criteria provided, single submitter |
| 3775881 | NM_000326.5(RLBP1):c.685-2A>G | RLBP1 | Likely pathogenic | criteria provided, single submitter |
| 3892291 | NM_000326.5(RLBP1):c.256G>T (p.Glu86Ter) | RLBP1 | Likely pathogenic | criteria provided, single submitter |
| 498474 | NM_000326.5(RLBP1):c.25C>T (p.Arg9Cys) | RLBP1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 812398 | NM_000326.5(RLBP1):c.602T>C (p.Ile201Thr) | RLBP1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 3064717 | NM_000326.5(RLBP1):c.467G>A (p.Arg156Gln) | RLBP1 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 317237 | NM_000326.5(RLBP1):c.647G>A (p.Arg216Gln) | RLBP1 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 860583 | NM_000326.5(RLBP1):c.304G>A (p.Ala102Thr) | RLBP1 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 378479 | NM_000326.5(RLBP1):c.684+20C>T | RLBP1 | Benign | criteria provided, multiple submitters, no conflicts |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 10 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| RLBP1 | Definitive | Autosomal recessive | Bothnia retinal dystrophy | 10 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| RLBP1 | Orphanet:227796 | Fundus albipunctatus |
| RLBP1 | Orphanet:52427 | Retinitis punctata albescens |
| RLBP1 | Orphanet:791 | Retinitis pigmentosa |
| RLBP1 | Orphanet:85128 | Bothnia retinal dystrophy |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| RLBP1 | HGNC:10024 | ENSG00000140522 | P12271 | Retinaldehyde-binding protein 1 | gencc,clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| RLBP1 | Retinaldehyde-binding protein 1 | Soluble retinoid carrier essential the proper function of both rod and cone photoreceptors. |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 1 | 1.8× | 0.558 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| RLBP1 | Other/Unknown | no | CRAL-TRIO_dom, CRAL/TRIO_N_dom, CRAL/TRIO_N_dom_sf |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| optic choroid | 1 |
| pigmented layer of retina | 1 |
| retina | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| RLBP1 | 126 | tissue_specific | marker | pigmented layer of retina, retina, optic choroid |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| RLBP1 | 1,078 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| RLBP1 | P12271 | 4 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 3. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Defective visual phototransduction due to RDH5 loss of function | 1 | 5710.0× | 5e-04 | RLBP1 |
| The retinoid cycle in cones (daylight vision) | 1 | 1631.4× | 9e-04 | RLBP1 |
| The canonical retinoid cycle in rods (twilight vision) | 1 | 519.1× | 0.002 | RLBP1 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| vitamin A metabolic process | 1 | 2407.4× | 8e-04 | RLBP1 |
| visual perception | 1 | 79.5× | 0.013 | RLBP1 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| RLBP1 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 1 | RLBP1 |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| RLBP1 | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: RLBP1